David S Black1,2, Steve W Cole3,4, Georgia Christodoulou1, Jane C Figueiredo1,5. 1. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. 2. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California. 3. Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 4. Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 5. Community and Population Health Research, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
BACKGROUND: Many cancer survivors experience fatigue as a nagging symptom lasting years after treatment. To learn of the relevant biological pathways involved in fatigue among cancer survivors, the authors tested for an association between fatigue levels and leukocyte gene expression profiles and determined the specific mediating immune cell types. METHODS: A sample of 89 Hispanic/Latino adults aged 60.5 years, 62% of whom were male, who were diagnosed with colorectal cancer and were 2.9 years since diagnosis provided blood for transcriptome profiling and completed a validated measure of fatigue (Multidimensional Fatigue Symptom Inventory-Short Form). The authors applied genome-wide transcriptional profiling of leukocyte RNA to identify gene expression activity associated with fatigue, tested for the activity of specific transcription factors involved in previously established markers of inflammation and immunologic activation, and identified the specific cell types mediating these transcriptional alterations. RESULTS: In analyses adjusting for demographic and behavioral health risk factors, results linked fatigue with increased activation of B lymphocytes and CD8-positive T cells, as well as several transcription factors involved in immune activation (nuclear factor κB [NF-κB], signal transducer and activator of transcription [STAT], and cAMP responsive element-binding protein [CREB]). Results also replicated several specific genomic effects previously observed in fatigued cancer survivors, including upregulated expression of α-synuclein (SNCA) and hemoglobin subunits (HBA and HBB). CONCLUSIONS: Cancer survivors' heightened fatigue levels may be partially explained by activation of specific immune cell subsets, thereby providing a potential molecular biomarker for clinical interventions targeting the remediation of fatigue. Cancer 2018;124:2637-44.
BACKGROUND: Many cancer survivors experience fatigue as a nagging symptom lasting years after treatment. To learn of the relevant biological pathways involved in fatigue among cancer survivors, the authors tested for an association between fatigue levels and leukocyte gene expression profiles and determined the specific mediating immune cell types. METHODS: A sample of 89 Hispanic/Latino adults aged 60.5 years, 62% of whom were male, who were diagnosed with colorectal cancer and were 2.9 years since diagnosis provided blood for transcriptome profiling and completed a validated measure of fatigue (Multidimensional Fatigue Symptom Inventory-Short Form). The authors applied genome-wide transcriptional profiling of leukocyte RNA to identify gene expression activity associated with fatigue, tested for the activity of specific transcription factors involved in previously established markers of inflammation and immunologic activation, and identified the specific cell types mediating these transcriptional alterations. RESULTS: In analyses adjusting for demographic and behavioral health risk factors, results linked fatigue with increased activation of B lymphocytes and CD8-positive T cells, as well as several transcription factors involved in immune activation (nuclear factor κB [NF-κB], signal transducer and activator of transcription [STAT], and cAMP responsive element-binding protein [CREB]). Results also replicated several specific genomic effects previously observed in fatigued cancer survivors, including upregulated expression of α-synuclein (SNCA) and hemoglobin subunits (HBA and HBB). CONCLUSIONS: Cancer survivors' heightened fatigue levels may be partially explained by activation of specific immune cell subsets, thereby providing a potential molecular biomarker for clinical interventions targeting the remediation of fatigue. Cancer 2018;124:2637-44.
Authors: Kathryn H Schmitz; Marian L Neuhouser; Tanya Agurs-Collins; Krista A Zanetti; Lisa Cadmus-Bertram; Lorraine T Dean; Bettina F Drake Journal: J Natl Cancer Inst Date: 2013-08-29 Impact factor: 13.506
Authors: Julienne E Bower; Patricia A Ganz; Michael R Irwin; Lorna Kwan; Elizabeth C Breen; Steve W Cole Journal: J Clin Oncol Date: 2011-08-08 Impact factor: 44.544
Authors: Barbara L Fredrickson; Karen M Grewen; Kimberly A Coffey; Sara B Algoe; Ann M Firestine; Jesusa M G Arevalo; Jeffrey Ma; Steven W Cole Journal: Proc Natl Acad Sci U S A Date: 2013-07-29 Impact factor: 11.205
Authors: Stephanie L Schmit; Fredrick R Schumacher; Christopher K Edlund; David V Conti; Ugonna Ihenacho; Peggy Wan; David Van Den Berg; Graham Casey; Barbara K Fortini; Heinz-Josef Lenz; Teresa Tusié-Luna; Carlos A Aguilar-Salinas; Hortensia Moreno-Macías; Alicia Huerta-Chagoya; María Luisa Ordóñez-Sánchez; Rosario Rodríguez-Guillén; Ivette Cruz-Bautista; Maribel Rodríguez-Torres; Linda Liliana Muñóz-Hernández; Olimpia Arellano-Campos; Donají Gómez; Ulices Alvirde; Clicerio González-Villalpando; María Elena González-Villalpando; Loic Le Marchand; Christopher A Haiman; Jane C Figueiredo Journal: Carcinogenesis Date: 2016-04-18 Impact factor: 4.944
Authors: Ido Amit; Manuel Garber; Nicolas Chevrier; Ana Paula Leite; Yoni Donner; Thomas Eisenhaure; Mitchell Guttman; Jennifer K Grenier; Weibo Li; Or Zuk; Lisa A Schubert; Brian Birditt; Tal Shay; Alon Goren; Xiaolan Zhang; Zachary Smith; Raquel Deering; Rebecca C McDonald; Moran Cabili; Bradley E Bernstein; John L Rinn; Alex Meissner; David E Root; Nir Hacohen; Aviv Regev Journal: Science Date: 2009-09-03 Impact factor: 47.728
Authors: Thomas W McDade; Chris W Kuzawa; Judith Borja; Jesusa M G Arevalo; Greg Miller; Steve W Cole Journal: J Dev Orig Health Dis Date: 2019-06-17 Impact factor: 2.401
Authors: Lauren V Ghazal; Steve Cole; John M Salsman; Lynne Wagner; Fenghai Duan; Ilana Gareen; Lauren Lux; Susan K Parsons; Christabel Cheung; David M Loeb; Pinki Prasad; Shira Dinner; Brad Zebrack Journal: JCO Precis Oncol Date: 2022-06
Authors: Alix G Sleight; Sylvia L Crowder; Jacek Skarbinski; Paul Coen; Nathan H Parker; Aasha I Hoogland; Brian D Gonzalez; Mary C Playdon; Steven Cole; Jennifer Ose; Yuichi Murayama; Erin M Siegel; Jane C Figueiredo; Heather S L Jim Journal: Cancers (Basel) Date: 2022-04-14 Impact factor: 6.575
Authors: Jennifer K MacCormack; Monica M Gaudier-Diaz; Emma L Armstrong-Carter; Jesusa M G Arevalo; Samantha Meltzer-Brody; Erica K Sloan; Steven W Cole; Keely A Muscatell Journal: Neuropsychopharmacology Date: 2021-01-15 Impact factor: 7.853
Authors: Steven W Cole; Michael J Shanahan; Lauren Gaydosh; Kathleen Mullan Harris Journal: Proc Natl Acad Sci U S A Date: 2020-02-10 Impact factor: 11.205